Article
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Molecular & cellular proteomics : MCP - 1 Nov 2018
Shraibman Bracha, Barnea Eilon, Kadosh Dganit Melamed, Haimovich Yael, Slobodin Gleb, Rosner Itzhak, López-Larrea Carlos, Hilf Norbert, Kuttruff Sabrina, Song Colette, Britten Cedrik, Castle John, Kreiter Sebastian, Frenzel Katrin, Tatagiba Marcos, Tabatabai Ghazaleh, Dietrich Pierre-Yves, Dutoit Valérie, Wick Wolfgang, Platten Michael, Winkler Frank, von Deimling Andreas, Kroep Judith, Sahuquillo Juan, Martinez-Ricarte Francisco, Rodon Jordi, Lassen Ulrik, Ottensmeier Christian, van der Burg Sjoerd H, Thor Straten Per, Poulsen Hans Skovgaard, Ponsati Berta, Okada Hideho, Rammensee Hans-Georg, Sahin Ugur, Singh Harpreet, Admon Arie
Abstract excerpt
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Furthermore, early detection of GBM, such as by a routine blood test, may improve survival, even with the current...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.